---
document_datetime: 2025-12-02 04:52:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/yorvipath.html
document_name: yorvipath.html
version: success
processing_time: 0.2782062
conversion_datetime: 2025-12-24 04:58:52.412911
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Yorvipath

[RSS](/en/individual-human-medicine.xml/77401)

##### Authorised

This medicine is authorised for use in the European Union

palopegteriparatide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Yorvipath](#news-on)
- [More information on Yorvipath](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Yorvipath is a hormone replacement medicine for treating adults with chronic hypoparathyroidism.

In patients with this condition, the parathyroid glands in the neck do not produce enough parathyroid hormone (PTH) which controls the level of calcium in the blood. As a result, patients have low levels of calcium and may experience problems with bones, muscles, the heart, kidneys and other parts of the body.

Hypoparathyroidism is rare, and Yorvipath was designated an 'orphan medicine' (a medicine used in rare diseases) on 19 October 2020. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-20-2350) .

Yorvipath contains the active substance palopegteriparatide.

Expand section

Collapse section

## How is Yorvipath used?

Yorvipath is given as an injection under the skin using a pre-filled pen. The medicine can only be obtained with a prescription. Treatment should be started and monitored by a doctor or a qualified healthcare professional experienced in the diagnosis and management of patients with chronic hypoparathyroidism.

For more information about using Yorvipath, see the package leaflet or contact your doctor or pharmacist.

## How does Yorvipath work?

The active substance in Yorvipath, palopegteriparatide, is changed in the body into teriparatide, a shortened form of PTH. Teriparatide replaces the missing hormone in patients with hypoparathyroidism, acting through bone tissue and the kidneys to help restore calcium levels.

## What benefits of Yorvipath have been shown in studies?

One main study involving 84 patients with hypoparathyroidism showed that Yorvipath was effective at keeping blood calcium levels within the normal range, compared with placebo. Around 79% (48 out of 61) of patients given Yorvipath for 26 weeks achieved normal blood calcium levels, no longer needed standard treatments (active vitamin D and high-dose calcium supplements) and were on a stable dose of the medicine. This compared with 5% (1 out of 21) of patients given placebo.

## What are the risks associated with Yorvipath?

For the full list of side effects and restrictions with Yorvipath, see the package leaflet.

The most common side effects with Yorvipath (which may affect more than 1 in 10 people) include injection site reactions, headache and paraesthesia (unusual sensations like pins and needles).

Yorvipath must not be used in patients who have pseudohypoparathyroidism, a condition in which the body does not adequately respond to the parathyroid hormone produced by the body.

## Why is Yorvipath authorised in the EU?

Yorvipath replaces the missing parathyroid hormone in patients with chronic hypoparathyroidism, and the results of the main study showed that most patients given the medicine had blood calcium levels within the normal range and no longer needed therapeutic doses of calcium supplements and active vitamin D to control their disease. In addition, side effects are considered to be manageable.

The European Medicines Agency therefore decided that Yorvipath's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Yorvipath?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yorvipath have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Yorvipath are continuously monitored. Side effects reported with Yorvipath are carefully evaluated and any necessary action taken to protect patients.

## Other information about Yorvipath

Yorvipath received a marketing authorisation valid throughout the EU on 17 November 2023.

Yorvipath : EPAR - Medicine overview

Reference Number: EMA/432465/2023

English (EN) (114.39 KB - PDF)

**First published:** 06/12/2023

[View](/en/documents/overview/yorvipath-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-366)

български (BG) (131.12 KB - PDF)

**First published:**

06/12/2023

[View](/bg/documents/overview/yorvipath-epar-medicine-overview_bg.pdf)

español (ES) (107.52 KB - PDF)

**First published:**

06/12/2023

[View](/es/documents/overview/yorvipath-epar-medicine-overview_es.pdf)

čeština (CS) (128.23 KB - PDF)

**First published:**

06/12/2023

[View](/cs/documents/overview/yorvipath-epar-medicine-overview_cs.pdf)

dansk (DA) (106.27 KB - PDF)

**First published:**

06/12/2023

[View](/da/documents/overview/yorvipath-epar-medicine-overview_da.pdf)

Deutsch (DE) (110.54 KB - PDF)

**First published:**

06/12/2023

[View](/de/documents/overview/yorvipath-epar-medicine-overview_de.pdf)

eesti keel (ET) (104.99 KB - PDF)

**First published:**

06/12/2023

[View](/et/documents/overview/yorvipath-epar-medicine-overview_et.pdf)

ελληνικά (EL) (130.91 KB - PDF)

**First published:**

06/12/2023

[View](/el/documents/overview/yorvipath-epar-medicine-overview_el.pdf)

français (FR) (108.64 KB - PDF)

**First published:**

06/12/2023

[View](/fr/documents/overview/yorvipath-epar-medicine-overview_fr.pdf)

hrvatski (HR) (128.21 KB - PDF)

**First published:**

06/12/2023

[View](/hr/documents/overview/yorvipath-epar-medicine-overview_hr.pdf)

italiano (IT) (105.94 KB - PDF)

**First published:**

06/12/2023

[View](/it/documents/overview/yorvipath-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (144.96 KB - PDF)

**First published:**

06/12/2023

[View](/lv/documents/overview/yorvipath-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (129.35 KB - PDF)

**First published:**

06/12/2023

[View](/lt/documents/overview/yorvipath-epar-medicine-overview_lt.pdf)

magyar (HU) (128.9 KB - PDF)

**First published:**

06/12/2023

[View](/hu/documents/overview/yorvipath-epar-medicine-overview_hu.pdf)

Malti (MT) (130.98 KB - PDF)

**First published:**

06/12/2023

[View](/mt/documents/overview/yorvipath-epar-medicine-overview_mt.pdf)

Nederlands (NL) (106.73 KB - PDF)

**First published:**

06/12/2023

[View](/nl/documents/overview/yorvipath-epar-medicine-overview_nl.pdf)

polski (PL) (131.53 KB - PDF)

**First published:**

06/12/2023

[View](/pl/documents/overview/yorvipath-epar-medicine-overview_pl.pdf)

português (PT) (108.08 KB - PDF)

**First published:**

06/12/2023

[View](/pt/documents/overview/yorvipath-epar-medicine-overview_pt.pdf)

română (RO) (125.83 KB - PDF)

**First published:**

06/12/2023

[View](/ro/documents/overview/yorvipath-epar-medicine-overview_ro.pdf)

slovenčina (SK) (127.83 KB - PDF)

**First published:**

06/12/2023

[View](/sk/documents/overview/yorvipath-epar-medicine-overview_sk.pdf)

slovenščina (SL) (126.26 KB - PDF)

**First published:**

06/12/2023

[View](/sl/documents/overview/yorvipath-epar-medicine-overview_sl.pdf)

Suomi (FI) (104.72 KB - PDF)

**First published:**

06/12/2023

[View](/fi/documents/overview/yorvipath-epar-medicine-overview_fi.pdf)

svenska (SV) (106.8 KB - PDF)

**First published:**

06/12/2023

[View](/sv/documents/overview/yorvipath-epar-medicine-overview_sv.pdf)

Yorvipath : EPAR - Risk management plan

English (EN) (2.1 MB - PDF)

**First published:** 06/12/2023

[View](/en/documents/rmp/yorvipath-epar-risk-management-plan_en.pdf)

## Product information

Yorvipath : EPAR - Product information

English (EN) (1.42 MB - PDF)

**First published:** 06/12/2023

**Last updated:** 20/06/2025

[View](/en/documents/product-information/yorvipath-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-383)

български (BG) (1.42 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/bg/documents/product-information/yorvipath-epar-product-information_bg.pdf)

español (ES) (1.25 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/es/documents/product-information/yorvipath-epar-product-information_es.pdf)

čeština (CS) (1.36 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/cs/documents/product-information/yorvipath-epar-product-information_cs.pdf)

dansk (DA) (1.32 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/da/documents/product-information/yorvipath-epar-product-information_da.pdf)

Deutsch (DE) (1.35 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/de/documents/product-information/yorvipath-epar-product-information_de.pdf)

eesti keel (ET) (1.33 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/et/documents/product-information/yorvipath-epar-product-information_et.pdf)

ελληνικά (EL) (1.46 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/el/documents/product-information/yorvipath-epar-product-information_el.pdf)

français (FR) (1.3 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/fr/documents/product-information/yorvipath-epar-product-information_fr.pdf)

hrvatski (HR) (1.35 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/hr/documents/product-information/yorvipath-epar-product-information_hr.pdf)

íslenska (IS) (1.38 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/is/documents/product-information/yorvipath-epar-product-information_is.pdf)

italiano (IT) (1.36 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/it/documents/product-information/yorvipath-epar-product-information_it.pdf)

latviešu valoda (LV) (1.38 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/lv/documents/product-information/yorvipath-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.43 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/lt/documents/product-information/yorvipath-epar-product-information_lt.pdf)

magyar (HU) (1.41 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/hu/documents/product-information/yorvipath-epar-product-information_hu.pdf)

Malti (MT) (1.46 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/mt/documents/product-information/yorvipath-epar-product-information_mt.pdf)

Nederlands (NL) (1.27 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/nl/documents/product-information/yorvipath-epar-product-information_nl.pdf)

norsk (NO) (1.28 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/no/documents/product-information/yorvipath-epar-product-information_no.pdf)

polski (PL) (1.41 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/pl/documents/product-information/yorvipath-epar-product-information_pl.pdf)

português (PT) (1.29 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/pt/documents/product-information/yorvipath-epar-product-information_pt.pdf)

română (RO) (1.45 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/ro/documents/product-information/yorvipath-epar-product-information_ro.pdf)

slovenčina (SK) (1.33 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/sk/documents/product-information/yorvipath-epar-product-information_sk.pdf)

slovenščina (SL) (3.03 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/sl/documents/product-information/yorvipath-epar-product-information_sl.pdf)

Suomi (FI) (1.25 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/fi/documents/product-information/yorvipath-epar-product-information_fi.pdf)

svenska (SV) (1.29 MB - PDF)

**First published:**

06/12/2023

**Last updated:**

20/06/2025

[View](/sv/documents/product-information/yorvipath-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000247280 10/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Yorvipath : EPAR - All authorised presentations

English (EN) (18.97 KB - PDF)

**First published:** 06/12/2023

**Last updated:** 14/11/2024

[View](/en/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-305)

български (BG) (41.34 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/bg/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_bg.pdf)

español (ES) (14.8 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/es/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39.62 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/cs/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (15.55 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/da/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.18 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/de/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (14.41 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/et/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.95 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/el/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_el.pdf)

français (FR) (14.95 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/fr/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (101.51 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/hr/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (14.75 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/is/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_is.pdf)

italiano (IT) (14.93 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/it/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (41.37 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/lv/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (37.78 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/lt/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (33.63 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/hu/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.2 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/mt/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.68 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/nl/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (15.13 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/no/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.81 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/pl/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_pl.pdf)

português (PT) (14.94 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/pt/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_pt.pdf)

română (RO) (39.81 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/ro/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (39.02 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/sk/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.99 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/sl/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (14.94 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/fi/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (14.78 KB - PDF)

**First published:**

06/12/2023

**Last updated:**

14/11/2024

[View](/sv/documents/all-authorised-presentations/yorvipath-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Yorvipath Active substance palopegteriparatide International non-proprietary name (INN) or common name palopegteriparatide Therapeutic area (MeSH) Hypoparathyroidism Anatomical therapeutic chemical (ATC) code H05AA

### Pharmacotherapeutic group

Calcium homeostasis

### Therapeutic indication

Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism

## Authorisation details

EMA product number EMEA/H/C/005934

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Ascendis Pharma Bone Diseases A/S

Tuborg Boulevard 12

Opinion adopted 14/09/2023 Marketing authorisation issued 17/11/2023 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Yorvipath : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (153.51 KB - PDF)

**First published:** 20/06/2025

[View](/en/documents/procedural-steps-after/yorvipath-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Yorvipath : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (109.19 KB - PDF)

**First published:** 11/04/2024

**Last updated:** 20/06/2025

[View](/en/documents/procedural-steps-after/yorvipath-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Yorvipath : Orphan Maintenance Assessment Report

Adopted

Reference Number: EMA/OD/0000140073

English (EN) (439.13 KB - PDF)

**First published:** 06/12/2023

[View](/en/documents/orphan-maintenance-report/yorvipath-orphan-maintenance-assessment-report_en.pdf)

Yorvipath : EPAR - Public assessment report

Adopted

Reference Number: EMA/439682/2023

English (EN) (6.12 MB - PDF)

**First published:** 06/12/2023

[View](/en/documents/assessment-report/yorvipath-epar-public-assessment-report_en.pdf)

CHMP summary of positive for Yorvipath

Draft

Reference Number: EMA/CHMP/405555/2023

English (EN) (131.37 KB - PDF)

**First published:** 15/09/2023

[View](/en/documents/smop-initial/chmp-summary-positive-yorvipath_en.pdf)

#### News on Yorvipath

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2023) 15/09/2023

#### More information on Yorvipath

- [EU/3/20/2350 - orphan designation for treatment of hypoparathyroidism](/en/medicines/human/orphan-designations/eu-3-20-2350)

**This page was last updated on** 20/06/2025

## Share this page

[Back to top](#main-content)